Co Diagnostics Ownership
| CODX Stock | USD 0.28 0.02 7.69% |
Shares in Circulation | First Issued 2015-12-31 | Previous Quarter 33.1 M | Current Value 32 M | Avarage Shares Outstanding 22.6 M | Quarterly Volatility 8.9 M |
CODX Stock Ownership Analysis
About 17.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.19. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co Diagnostics recorded a loss per share of 1.17. The entity had not issued any dividends in recent years. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more info on Co Diagnostics please contact Dwight Egan at (801) 438-1036 or go to https://co-dx.com.CODX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Co Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Co Diagnostics backward and forwards among themselves. Co Diagnostics' institutional investor refers to the entity that pools money to purchase Co Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Squarepoint Ops Llc | 2025-03-31 | 65.8 K | Northern Trust Corp | 2025-03-31 | 55 K | Virtu Financial Llc | 2025-03-31 | 54.2 K | Xtx Topco Ltd | 2025-03-31 | 47.9 K | Jane Street Group Llc | 2025-03-31 | 40.1 K | Two Sigma Securities, Llc | 2025-03-31 | 29.4 K | Uma Financial Services Inc | 2025-03-31 | 28.4 K | Smi Advisory Services Llc | 2025-03-31 | 28 K | Rathbone Brothers Plc | 2025-03-31 | 25 K | Vanguard Group Inc | 2025-03-31 | 1.8 M | Private Asset Group Llc | 2025-03-31 | 1.2 M |
Co Diagnostics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Co Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Co Diagnostics Outstanding Bonds
Co Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Co Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CODX bonds can be classified according to their maturity, which is the date when Co Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| CNO 175 07 OCT 26 Corp BondUS18977W2A75 | View | |
| CNO 265 06 JAN 29 Corp BondUS18977W2C32 | View | |
| US189754AC88 Corp BondUS189754AC88 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.